Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03309241 · ClinicalTrials.gov registry record · Phase 1
First In Human, Single Escalating Oral Dose Study Of PF-06882961 In Healthy Adult Subjects
A Phase 1 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 25
- Enrollment target
NCT03309241 is a Phase 1 study that has completed, run by Pfizer. The registered enrollment target is 25 participants.
The verdict
NCT03309241, a Phase 1 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 25 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of single oral doses of PF-06882961 in healthy adult subjects. This is the first clinical study of PF-06882961.
Interventions
- OTHER Placebo
- DRUG PF-06882961
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2017-10-17 |
| Est. Completion | 2018-03-22 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03309241
The ClinicalTrials.gov registry entry for NCT03309241 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03309241 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03309241 about?
NCT03309241 is a clinical study titled "First In Human, Single Escalating Oral Dose Study Of PF-06882961 In Healthy Adult Subjects". The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of single oral doses of PF-06882961 in healthy adult subjects. This is the first clinical study of PF-06882961.
What is the current status of trial NCT03309241?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 2017-10-17. Estimated completion is 2018-03-22.
What interventions are being tested in trial NCT03309241?
The interventions under investigation include: Placebo (OTHER), PF-06882961 (DRUG).
Who is sponsoring clinical trial NCT03309241?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.